 北京时间2015年6月10日，安诺优达基因科技（北京）有限公司和美国Illumina公司（NASDAQ：ILMN）在北京和美国圣迭戈同时宣布双方就联合开发应用于生育健康的高通量测序平台进行合作。该合作表明基因组学技术在改善中国医疗水平中的作用日益重要。 近年来，高通量测序技术发展迅猛，而且被视作是实现精准医学的关键因素之一。安诺优达和Illumina的合作将聚焦于为临床应用市场提供最先进的整体解决方案，而且双方将联合为中国市场开发便于用户操作的产前DNA检测平台。 本次合作将把Illumina的测序技术和安诺优达先进的临床应用转化能力有机地结合在一起。作为协议的一部分，安诺优达将提供自主开发的核酸提取、文库构建技术和数据分析软件，Illumina将提供高通量测序仪的零部件和相关试剂，以用于双方的合作开发。 “我们在推动国内基因组学技术的临床应用方面已经开展了一系列工作。无创产前DNA检测在生育健康领域已经得到了广泛运用，我们希望促进该技术成为医院的常规检测。”安诺优达创始人、首席执行官梁峻彬博士表示，“作为国家卫计委首批高通量测序临床应用试点单位，安诺优达非常乐意与全球测序及生物芯片技术的行业领袖Illumina合作。我们双方的合作将为生育健康领域提供更高质量的临床解决方案。” Illumina高级副总裁、生育与遗传健康事业部总经理Tristan Orpin表示：“Illumina很高兴与安诺优达合作，从而更好地为中国市场提供生育健康方面的解决方案。我们的愿景是通过诠释基因组来改善人类健康，我们一直致力于与拥有同样愿景的中国公司合作。” 关于安诺优达： 安诺优达总部位于北京，是中国基因组行业的知名企业，专注于新一代基因组学技术在人类医学健康和生命科学研究两大领域的产业化应用。基于其在中国市场和高通量测序行业的领先地位，安诺优达被认定为国家级高新技术企业，获得了国家卫计委首批高通量测序临床应用试点单位资质，在生育健康、肿瘤诊治、罕见病等领域开发了一系列高通量测序临床应用方案，并形成了优秀的产品体系和品牌效应。在科技服务领域，安诺优达qixia子品牌安诺基因为科研机构提供行业一流的高通量测序和生物信息分析整体解决方案。 关于Illumina Illumina 致力于通过诠释基因组来改善人类健康。基于其测序技术的持续创新，Illumina 成为全球DNA测序和生物芯片技术领域的行业领袖，为科研、临床和应用市场提供服务，产品涵盖生命科学、肿瘤学、生育健康、农业和其他新兴领域。更多详情见：www.illumina.com 并请关注@illumina。 Annoroad and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health BEIJING and SAN DIEGO—June10, 2015-- Annoroad and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China. In recent years, NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine. The collaboration between Annoroad and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market. In particular, the two companies will work together to develop a user-friendly, prenatal DNA diagnostic system for the Chinese market. The collaboration will bring together technology from Illumina sequencers with Annoroad’s advanced clinical application development capabilities. As part of the agreement, Annoroad will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents. "We have been working to promote the clinical application of genomic technology in China. Non-invasive prenatal testing is used widely in the reproductive health arena, and we hope to promote it as a standard practice in hospitals. As one of the first national clinical pilot sites forNGS appointed by the National Health and Family Planning Commission (formerly the Ministry of Health), Annoroad is now very pleased to partner with Illumina, the global leader in sequencing and array technologies. Cooperation between our two companies will provide additional high-quality diagnostic solutions in the field of reproductive health," said Junbin Liang, Annoroad Founder and Chief Executive Officer. “Illumina is very excited to collaborate with Annoroad to increase access to reproductive health solutions in China,” said Tristan Orpin, Senior Vice President and General Manager of Illumina’s Reproductive and Genetic Health business. “We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome.” About Annoroad Annoroad is headquartered in Beijing, China and is a well-known enterprise in the genomic industry in China. The company is committed to providing cutting edge genomic solutions in both clinical testing and life science research. Annoroad was entitled as the National High Innovative Technology Enterprise, and charted as the national clinical pilot site of NGS in Chinagiven its major position in the domestic market and next-gen sequencing technology. Annoroad has developed serials of NGS diagnostic applications in the field ofhuman reproduction, cancer, and rare diseases, forming the excellent product system and market brand. In the field of science and technology service,Annoroad provides state-of-the-art sequencing and bioinformatics solutions for research organizations under its sub-brand. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and otheremerging segments. To learn more, visit www.illumina.com and follow @illumina. |
/3 
浙公网安备33010802005999号 
